Market Overview

UPDATE: Morgan Stanley Reiterates on Pfizer as Vaccine Pipeline is Under-Appreciated

Share:
Related PFE
Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'
5 Biggest Price Target Changes For Tuesday
Security National Bank Of Sioux City Iowa Buys Baker Hughes Inc, iShares U.S. ... (GuruFocus)

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), and raised the price target from $34.00 to $36.00.

In the report, Morgan Stanley noted, “We believe Pfizer can outperform the pharma group given its potential for positive pipeline news and strategic action. Mgmt is committed to share repurchase and dividend increases. Financial and strategic action should continue to drive shareholder value.”

Pfizer closed on Thursday at $31.12.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2017BMO CapitalUpgradesMarket PerformOutperform
Jul 2017Credit SuisseMaintainsNeutral
Jul 2017Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!